Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Public Health

Varicella control and vaccine coverage: issues and challenges

Tamara Wallington and Erica Weir
CMAJ March 05, 2002 166 (5) 631-632;
Tamara Wallington
*Community Medicine, McMaster University; **
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica Weir
*Community Medicine, McMaster University; **
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Background and epidemiology: Varicella zoster virus (VZV) is a DNA virus belonging to the herpesvirus family. It causes a primary illness commonly known as chickenpox and can also lie latent in the sensory nerve ganglia until it reactivates later in life and causes herpes zoster (shingles). The lifetime risk of VZV infection is about 95%,1 with about 350 000 cases reported annually in Canada. Disease tracking is currently based on passive reporting from 6 provinces and 2 territories, and it likely underestimates the true incidence of infection by a factor of 5 or more.2

Figure

Figure. Varicella, an uncomfortable reality for most children, occasionally leads to more serious complications.

Most (90%) reported cases of VZV infection involve uncomplicated cases of chickenpox in children.2 The uncomplicated disease, despite its benign course, carries an economic burden of about $109.2 million annually, with direct medical costs accounting for only about 10% of this; the largest cost driver is lost productivity caused by caregivers' lost work days.3

Severe complications such as superimposed skin infections (group A β-hemolytic streptococci), encephalitis and pneumonia develop in a small proportion of patients. The risk of severe complications from primary VZV infection is much higher in adults than in children. Adults account for only 5% of all annual cases, yet between 1987 and 1996 they represented about 70% of reported VZV-related deaths in Canada.4 Maternal infection during the first 28 weeks of gestation can transmit VZV to the fetus and lead to congenital varicella syndrome.

VZV infection, which is highly contagious, is spread by direct contact with skin lesions or oral secretions; airborne spread can also occur. Those infected are contagious from 1 to 2 days before the onset of rash up until the last lesion has crusted. The incubation period ranges from 10 to 21 days, and there may be prodromal symptoms such as fever, malaise and upper respiratory tract infection. The characteristic lesions appear in successive crops over the first 3 to 4 days and progress from macules to vesicles to pustules to crusted lesions.4 The rash is generally centrally distributed, with lesions concentrated on the trunk, scalp and face.

Diagnosis can be made clinically by the characteristic rash and epidemiologic links such as known exposure to another patient.1 The virus can be isolated from scrapings of the vesicle base during the first 3 to 4 days after the eruption as well as from a variety of serologic antibody tests. A significant increase in serum varicella IgG antibody can retrospectively confirm a diagnosis in immunocompetent people.5

Clinical management: The care given to otherwise healthy individuals who have an uncomplicated course of VZV infection is primarily supportive. Intravenous or oral therapy with acyclovir, valacyclovir, famciclovir or foscarnet can be given. The decision to use antiviral therapy, and the duration and route, will depend on a variety of specific host factors and the extent of infection.5

Prevention and control: Varicella is a notifiable disease. When treating a patient, physicians should follow the recommended precautions for airborne diseases in the infection control guidelines for the physician's office.6 This includes quickly triaging such patients out of the common waiting area and, if possible, seeing them at the end of the day. Health care workers who are not immune to the disease should not enter the room, and routine housekeeping measures as outlined in section 4 of the guidelines should be followed.6 Susceptible health care workers may also consider vaccination — the National Committee on Immunization4 and the Canadian Task Force on Preventive Health Care7 both recommend primary vaccination of healthy people over 12 months of age who are susceptible to the disease. People older than 13 years should receive 2 full doses at least 28 days apart.1

A live attenuated vaccine called the Oka strain was developed in Japan, in the early 1970s. Until June 2000 the only varicella vaccine licensed for use in Canada was highly heat sensitive, but it has been replaced with a vaccine that offers better stability at fridge temperature.

Despite the advent of a more stable vaccine, health care professionals do not universally accept routine administration of the varicella vaccine because it is unclear whether lifelong immunity will develop in children who are vaccinated. It is currently estimated that the vaccine offers about 70%–90% protection against VZV of any severity for at least 7 to 10 years, which is the observation period reported from recent studies.1,8,9,10,11 If the protective effect wanes, a program of universal vaccination could cause a shift in the epidemiology of varicella to the adult population, with a resulting increase in morbidity.3,12 This would put susceptible adults at increased risk of the disease at an age when significant complications are common.12

Tamara Wallington Community Medicine McMaster University Erica Weir CMAJ

References

  1. 1.↵
    Varicella-zoster virus disease and epidemiology: seeking better control strategies — Part 1. Can Commun Dis Rep 1998;24(24). Available: www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/98vol24/dr2424ea.html (accessed 2002 Jan 31).
  2. 2.↵
    Varicella: highlights on current issues and challenges. Paediatr Child Health 1999;4(Suppl C).
  3. 3.↵
    Law B, Fitzsimon C, Ford-Jones L, MacDonald N, Dery P, Vaudry W, et al. Cost of chickenpox in Canada: part 1. Cost of uncomplicated cases. Pediatrics 1999;104:1-6.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    National Committee on Immunization. Statement on recommended use of varicella virus vaccine. Can Commun Dis Rep 1999;25(ACS-1). Available: www .hc-sc.gc.ca/hpb/lcdc /publicat /ccdr /99vol25 /25 sup /acs1.html (accessed 2002 Jan 31).
  5. 5.↵
    Report of the Committee on Infectious Diseases. Red book. 25th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2000.
  6. 6.↵
    Infection control in the physician's office. Toronto: College of Physicians and Surgeons of Ontario; 1999.
  7. 7.↵
    Varicella vaccination: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2001;164(13):1888-9. Available: www.cma.ca/cmaj/vol-164/issue-13/1888.asp
    OpenUrlFREE Full Text
  8. 8.↵
    Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 1984;310:1409-15.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985:75:667-71.
  10. 10.↵
    Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9:643-7.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78(Suppl):748-56.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Taylor J. Herd Immunity and the varicella vaccine. Is it a good thing? Arch Pediatr Adolesc Med 2001; 155(4):440-1.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 166, Issue 5
5 Mar 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Varicella control and vaccine coverage: issues and challenges
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Varicella control and vaccine coverage: issues and challenges
Tamara Wallington, Erica Weir
CMAJ Mar 2002, 166 (5) 631-632;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Varicella control and vaccine coverage: issues and challenges
Tamara Wallington, Erica Weir
CMAJ Mar 2002, 166 (5) 631-632;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Varicella vaccine update: Need for a booster?
  • Google Scholar

More in this TOC Section

  • Seasonal drinking: Let's avoid the “January effect”
  • Influenza in children
  • Latent tuberculosis: revised treatment guidelines
Show more Public Health

Similar Articles

Collections

  • Topics
    • Infectious diseases
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire